Metabolic Research

Tesamorelin

GHRH(1–44) analogue

Also known as TH9507.

A stabilised analogue of growth-hormone-releasing hormone with a trans-3-hexenoyl N-terminal modification, studied in GHRH-receptor and visceral-adiposity models.

Current lot: SN-TES-2606
Purity: 99.29% by HPLC
Tested: Jun 22, 2026
Stocked in: United States, Canada

Synamino Sciences research vial with a silver cap on a navy background

Ships from

Vial size

$69.00

USD · 10 mg · In stock

Qty

Order by 2:00 PM PT for same-day dispatch from Reno, Nevada. 1–3 business days by USPS Priority and UPS. Free shipping over $150.00.

For laboratory research use only. Not for human or veterinary use.

About the compound

Tesamorelin preserves the full 44-residue GHRH sequence while the N-terminal modification protects against dipeptidyl-peptidase cleavage. It is used in GHRH-receptor pharmacology and body-composition research.

Supplied as a lyophilized powder.

Studied inGHRH receptor · Visceral adiposity models · Secretagogue pharmacology

Certificate of analysis

The certificate for the lot currently shipping. Every vial in that lot carries the same lot number on its label.

Certificate of analysis

Tesamorelin · 10 mg

Lot SN-TES-2606 · tested Jun 22, 2026

99.29%

Purity by HPLC

Labeled: 10 mg
Measured: 10.2 mg
Panel: 6 passed · 2 reported
Laboratory: Independent ISO/IEC 17025 accredited laboratory

Assay	Method	Result	Outcome
Appearance	Visual	White lyophilized powder	Pass
Purity	HPLC · spec ≥ 98%	99.29%	Pass
Net peptide content	HPLC	10.2 mg	Reported
Identity	LC-MS	Confirmed	Pass
Heavy metals	ICP-MS	Not detected	Pass
Sterility	USP <71>	No growth	Pass
Endotoxin	LAL · USP <85>	< 0.05 EU/mL	Reported
Residual solvents	GC-HS	Within limits	Pass

Specification and storage

CAS number: 218949-48-5
Molecular formula: C221H366N72O67S
Molecular weight: 5135.9 g/mol
Residues: 44
Sequence: (E)-3-hexenoyl-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2
Reference record: PubChem entry

Storage

Sealed lyophilized vials are stable at room temperature for short periods; store at 2–8 °C for routine use.
For long-term storage keep sealed vials at −20 °C, protected from light and moisture.
Reconstituted solutions should be refrigerated at 2–8 °C and used within the period defined by your laboratory's protocol.

Literature

Peer-reviewed publications on this compound. Provided for reference; they are not claims about this product.

01
Annals of Pharmacotherapy · 2012
Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy
Spooner LM, Olin JL
02
The Journal of Clinical Endocrinology & Metabolism · 2010
Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data
Falutz J, Mamputu JC, Potvin D, et al.
03
AIDS · 2008
Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation
Falutz J, Allas S, Mamputu JC, et al.

Studied alongside

Ipamorelin
Pentapeptide GHS-R agonist
from $32.00
CJC-1295 (No DAC)
Modified GRF 1–29
from $38.00

Research notice

Tesamorelin is supplied for in vitro laboratory research and analytical use by qualified professionals. It is not a medicine, supplement or cosmetic, has not been evaluated by any regulator, and is not for human or veterinary use. Published findings cited on this page are provided for reference and are not claims about this product.